

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# **EPS Creative Health Technology Group Limited**

(Incorporated in the Cayman Islands with limited liability)

(HKEX Stock code: 3860)

- (1) APPOINTMENT OF EXECUTIVE DIRECTOR;**
- (2) RESIGNATION AND APPOINTMENT OF  
NON-EXECUTIVE DIRECTOR;**
- (3) REDESIGNATION OF DIRECTOR AND CHIEF EXECUTIVE OFFICER;**
- (4) APPOINTMENT OF CHIEF OPERATING OFFICER AND  
CHIEF STRATEGY OFFICER; AND**
- (5) CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The Board hereby announces the following appointments and resignations with effect from 12 July 2022:

- (1) Mr. Miyano has been appointed as an executive Director;
- (2) Mr. Liang has tendered his resignation as a non-executive Director;
- (3) Mr. Xia has been appointed as a non-executive Director;
- (4) Mr. Okoso has been redesignated from a non-executive Director to an executive Director;
- (5) Mr. Gao has been redesignated from the Chief Executive Officer to the Chief Strategy Officer;
- (6) Mr. Okoso has been appointed as the Chief Executive Officer;
- (7) Mr. Miyano has been appointed as the Managing Director and the Chief Operating Officer;
- (8) Mr. Gao has ceased to be a member of the nomination committee of the Company, and Mr. Miyano has been appointed as a member of the nomination committee of the Company in his place.

- (9) Mr. Liang has ceased to be a member of the audit committee of the Company, and Mr. Xia has been appointed as a member of the audit committee of the Company in his place.

## APPOINTMENT OF DIRECTORS

The board (the “**Board**”) of directors (the “**Directors**”) of EPS Creative Health Technology Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Miyano Tsumoru (“**Mr. Miyano**”) has been appointed as an executive Director and Mr. Xia Xiangming (“**Mr. Xia**”) has been appointed as a non-executive Director, both with effect from 12 July 2022. A brief summary of the biographical details of Mr. Miyano and Mr. Xia are set out below:

### Mr. Miyano

Mr. Miyano (宮野積), aged 56, is an executive officer of EPS Holdings, Inc. (“**EPS Japan**”, together with its subsidiaries, the “**EPS Japan Group**”), a company incorporated in Japan in 1991 with limited liability, the shares of which were formerly listed on the Tokyo Stock Exchange (stock code: 4282.T) until September 2021, which is a controlling shareholder (as defined under the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”)) of the Company. Mr. Miyano joined the EPS Japan Group in January 2002 and has over 31 years of experience in the domestic pharmaceutical industry in Japan and has extensive experience in business development and marketing. From 2005 up to 2016, Mr. Miyano had been the executive director of Simian Conservation Breeding & Research, Inc.

Mr. Miyano graduated from the Faculty of Agriculture of the Tokyo University of Agriculture and Technology in March 1991.

Pursuant to the letter of appointment entered into between the Company and Mr. Miyano, he has been appointed for a term of two years commencing from 12 July 2022 and is subject to the provision of retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. According to the terms of the letter of appointment, Mr. Miyano is entitled to a monthly salary of HK\$50,000 on a 13-month basis and a year-end discretionary bonus, which has been recommended by the remuneration committee of the Company (the “**Remuneration Committee**”) and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

### Mr. Xia

Mr. Xia Xiangming (夏向明), aged 60, has been an executive officer of EPS Japan since October 2018. Prior to that, Mr. Xia had been the general manager and deputy chairman of EPS CHINA CO., LTD from December 2008 to October 2018, the chief representative of 日本Conress株式會社北京事務所\* (the Beijing office of Japan Conress Kabushiki Kaisha) from December 2002 to October 2018 and the head of division, deputy chief and general representative in Japan of the China Council for the Promotion of International Trade from July 1987 to December 2002.

Mr. Xia obtained a bachelor's degree from Okayama University of Science in March 1985 and a master's degree in Science from the Graduate School of Science of Okayama University in March 1987.

Pursuant to the letter of appointment entered into between the Company and Mr. Xia, he has been appointed for a term of two years commencing from 12 July 2022 and is subject to the provision of retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. According to the terms of the letter of appointment, Mr. Xia is entitled to a director's fee of HK\$10,000 per month, which has been recommended by the Remuneration Committee and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

As at the date of this announcement, save as disclosed above, each of Mr. Miyano and Mr. Xia (i) does not hold any other position with the Company or any of its subsidiaries; (ii) has not held any other directorship in, or direct or indirect interest in 10% or more of the issued share capital of, any other public companies the securities of which are listed on any security market in Hong Kong or overseas in the three years prior to the date of this announcement; (iii) does not have any relationship with any directors, senior management or substantial or controlling shareholders (as defined under the Listing Rules) of the Company; and (iv) does not have any interest in the shares or underlying shares in the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) (the "SFO").

Save as disclosed above, there is no information relating to the appointment of Mr. Miyano and Mr. Xia that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, and there are no other matters in relation to their appointment that need to be brought to the attention of the shareholders of the Company (the "Shareholders").

## **RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The Board also announces that Mr. Liang Fei ("**Mr. Liang**") has tendered his resignation as a non-executive Director with effect from 12 July 2022 due to his desire to focus on his other business engagements. After the resignation of Mr. Liang as a non-executive Director, he will remain as the General Manager of the operation of the Group in the People's Republic of China.

Mr. Liang has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of the Shareholders and the Stock Exchange.

## **REDESIGNATION OF DIRECTOR**

The Board is pleased to announce that with effect from 12 July 2022, Mr. Okoso Satoshi ("**Mr. Okoso**") has been re-designated from a non-executive Director to an executive Director of the Company.

Mr. Okoso's biographical details are set out below.

Mr. Okoso Satoshi (大社聡) (“**Mr. Okoso**”), aged 63, was appointed as a non-executive Director with effect from 1 June 2021. Mr. Okoso is an executive officer of EPS Japan and has over 35 years of experience in clinical research, pharmacoepidemiology and healthcare industry. Mr. Okoso joined EPS Japan in 2015 and prior to joining EPS Japan, Mr. Okoso worked and held senior management positions at several clinical research and pharmaceutical companies in Japan. Mr. Okoso graduated from the Department of Agriculture and Veterinary Medicine of Nihon University, and worked on pharmacoepidemiological research in the Graduate School of Medicine and Faculty of Medicine of the University of Tokyo.

As at the date of this announcement, save as disclosed above, Mr. Okoso (i) does not hold any other position with the Company or any of its subsidiaries; (ii) has not held any other directorship in, or direct or indirect interest in 10% or more of the issued share capital of, any other public companies the securities of which are listed on any security market in Hong Kong or overseas in the three years prior to the date of this announcement; (iii) does not have any relationship with any directors, senior management or substantial or controlling shareholders (as defined under the Listing Rules) of the Company; (iv) does not have any interest in the shares or underlying shares in the Company (within the meaning of Part XV of the SFO).

Save as disclosed above, there is no information relating to the appointment of Mr. Okoso that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, and there are no other matters in relation to his redesignation that need to be brought to the attention of the Shareholders.

## **REDESIGNATION OF CHIEF EXECUTIVE OFFICER AND APPOINTMENT OF CHIEF OPERATING OFFICER AND CHIEF STRATEGY OFFICER**

Following the above changes to the Board, with effect from 12 July 2022:

- (1) Mr. Gao Feng (“**Mr. Gao**”), an executive Director, has been re-designated from Chief Executive Officer to Chief Strategy Officer of the Company;
- (2) Mr. Okoso, now an executive Director, has been appointed as the Chief Executive Officer; and
- (3) Mr. Miyano, an executive Director, has been appointed as the Managing Director and the Chief Operating Officer.

Following the above changes, Mr. Okoso will be both the chairman of the Board and the Chief Executive Officer of the Company. Mr. Okoso is an executive officer of EPS Japan and has over 35 years of experience in clinical research, pharmacoepidemiology and healthcare industry. He has been the chairman of the Board since 30 June 2021. As Mr. Gao, the former Chief Executive Officer has been redesignated to his new role of Chief Strategy Officer of the Company, Mr. Okoso, who has many years of experience in senior management positions, has taken up the role of Chief Executive

Officer of the Company. The Directors consider that vesting the roles of the chairman of the Board and the Chief Executive Officer of the Company in Mr. Okoso is beneficial to the management and the business developments of the Group and will provide a strong and consistent leadership to the Group. The Board will continue to review and consider splitting the roles of the chairman of the Board and the Chief Executive Officer of the Company as and when appropriate and suitable by taking into account the circumstances of the Group as a whole.

## **CHANGE IN COMPOSITION OF THE BOARD COMMITTEES**

The Board also announces that, following the change of the Board and with effect from 12 July 2022:

- (1) Mr. Gao has ceased to be a member of the nomination committee of the Company and Mr. Miyano has been appointed as a member of the nomination committee of the Company in his place; and
- (2) Mr. Liang has also ceased to be a member of the audit committee of the Company and Mr. Xia has been appointed as a member of the audit committee of the Company in his place.

The Board would like to take this opportunity to express its warmest welcome to Mr. Miyano and Mr. Xia for joining the Board and to Mr. Gao and Mr. Okoso in their new roles. The Board would also like to take this opportunity to express its sincere gratitude to Mr. Liang for his contribution to the Company during his tenure of office.

By order of the Board  
**EPS Creative Health Technology Group Limited**  
**Gao Feng**  
*Executive Director*

Hong Kong, 12 July 2022

*As at the date of this announcement, the executive Directors are Mr. Okoso Satoshi, Mr. Miyano Tsumoru, Mr. Gao Feng and Mr. Haribayashi Keikyo; the non-executive Director is Mr. Xia Xiangming; and the independent non-executive Directors are Mr. Taguchi Junichi, Mr. Choi Koon Ming and Mr. Chan Cheuk Ho.*

*The English names of Chinese entities marked with “\*” are translations of their Chinese names and are included in this circular for identification purpose only, and should not be regarded as their official English translation. In the event of any inconsistency, the Chinese name prevails.*